TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A U.S. Customs and Border Protection rule will suspend the under-$800 de minimis exemption for international mail beginning Oct. 22, adding data and bond requirements. The change does not specifically target Canadian medicines, but patients and advocates warn it could delay or block personal drug shipments and raise costs; the scale of the impact is not yet known.
A U.S. Customs and Border Protection (CBP) rule scheduled to take effect Oct. 22 will suspend a customs exemption for low-value international shipments, potentially making it harder for Americans to receive prescription medicines ordered from Canada. The measure applies to international mail generally, not specifically Canadian drugs, but patients and advocates say its new data and bond requirements could disrupt access to less expensive medicines.
The rule suspends the de minimis exemption, which previously let shipments valued below $800 pass through customs more easily. Once the suspension begins, medications mailed from outside the United States will require additional shipment data and a bond guarantee. The rule also adds fees and registration requirements for low-value goods across categories including textiles and toys. The report says these changes could lead to delays, refusals or greater difficulty delivering medicines, but does not establish how many prescriptions will be affected.
An estimated 2.3 million Americans bought drugs abroad, according to a 2020 study published in JAMA Network Open. The figure describes the study’s estimate of people purchasing drugs abroad; it does not establish how many rely on mail shipments from Canada or how many would face delivery problems under the new rule.
Ken Hunter, executive director of the Campaign for Personal Prescription Importation, cited a study by his organization comparing prices for 10 commonly prescribed drugs imported from Canada. He said a three-month supply of apixaban (Eliquis)—180 five-milligram pills—cost $565 from a Canadian mail-order pharmacy, compared with about $1,017 through Amazon’s pharmacy business and $1,029 through GoodRx. Those are the prices cited in the report; the source does not establish that every patient can obtain the same prices or that they will change by the same amount.
Access to Lower-Cost Medicines at Risk
For patients who use overseas pharmacies because of prices or the availability of a particular medicine, added border requirements could affect both delivery reliability and out-of-pocket costs. If a shipment is delayed or cannot be delivered, patients may need to seek another supply route or pay more through a U.S. seller. The report does not confirm that the rule will cause specific medicines to become unavailable, and its effects may vary by shipment and patient.
The issue also tests how the administration’s drug-price agenda interacts with customs enforcement. President Donald Trump has promoted lower prescription prices through most-favored-nation deals with drugmakers and the TrumpRx discounted-drug website. Patient advocates argue those efforts may not cover every medicine or person, while the customs rule could complicate one route some Americans use to find cheaper prescriptions.
Popular right now
Vitamix 5200 Professional-Grade Blender, 64 oz. Container, Black
Dyson V8 Cyclone Cordless Vacuum
Bose QuietComfort Ultra Wireless Noise-Cancelling Headphones with Spatial Audio, Black
As an affiliate, we earn on qualifying purchases.
The Exemption and Drug-Price Debate
The de minimis exemption applied to shipments valued under $800, allowing them to enter with fewer customs procedures. The new rule is broader than prescription imports: the source describes it as covering international mail and says it is intended to collect tariffs and prevent illegal drugs from entering the country. It does not say the measure was designed specifically to restrict Canadian pharmacy orders.
The dispute comes amid political attention to the cost of living and prescription medicines. Federal data cited in the report showed U.S. prescription drug prices were 3.1% lower year over year in data from that summer, the steepest annual decline since 1963. Trump has credited his policies, while experts cited by the report said factors beyond his administration’s actions likely contributed more to the drop. The report does not identify those factors in detail.
Political concern has crossed party lines. Three Florida Republican representatives—Aaron Bean, Gus M. Bilirakis and C. Scott Franklin—wrote to the administration about possible effects on constituents. More than 70 Democrats separately urged health and immigration enforcement officials to pause the rule unless they could assure that medicines for personal use would remain able to enter the country.
“The Trump administration continues working to ensure Americans have access to low-cost pharmaceuticals across the board.”
— Allison Schuster, White House spokesperson
How Shipments Will Be Handled
The report does not specify how CBP will apply the new requirements to individual prescription shipments, what fees patients may face, or how often packages could be delayed, rejected or returned. It is also unclear whether the administration will change the rule, delay it or choose not to enforce it. CBP representatives did not respond to the report’s requests for comment.
The source report’s account of patient Susan Hooper’s rising medication costs is incomplete: it says theophylline previously cost $85 with shipping and had become more expensive after additional tariffs on Canada were imposed in August, but the text provided ends before giving the new price. No exact increase can be stated from the available material.
Nor does the report establish that Canadian pharmacies will stop shipping medicines to U.S. customers. The practical effects could depend on customs implementation and how pharmacies, carriers and patients respond. A federal authorization for a Florida Canadian prescription importation program has also stalled, according to the report, but it provides no timetable for that initiative.
Oct. 22 Rule and Agency Response
The immediate milestone is the rule’s scheduled Oct. 22 start date. The administration could drop or alter the rule, or decide not to enforce it, according to the report. Lawmakers have asked federal officials how they will protect access to affordable medicines, but the source provides no response or announced policy change.
Patients, pharmacies and carriers will need clearer guidance on what information and bond guarantees are required for medication shipments and how officials will handle packages that do not meet those requirements. The effect on delivery times, pharmacy participation and patient costs will become clearer only after the rule takes effect or the government issues further instructions.
Key Questions
What changes on Oct. 22?
CBP is scheduled to suspend the de minimis exemption for low-value international shipments. The report says medicines mailed from outside the United States will then require additional data and a bond guarantee. The year is not specified in the source.
Does the rule specifically target Canadian prescription drugs?
No. The source describes a rule for international mail generally, covering many goods. Canadian medicine shipments could be affected as part of that broader policy, but they are not the rule’s stated specific target.
How many Americans may be affected?
A 2020 JAMA Network Open study estimated that about 2.3 million Americans bought drugs abroad. That figure is not an estimate of how many rely on Canadian mail-order pharmacies or will experience delivery problems under the rule.
Could the rule be changed or stopped?
The report says the administration could drop the rule, alter it or decide not to enforce it. Lawmakers from both parties have raised concerns, but no change or pause is confirmed in the material provided.
Source: rss
